Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels
- 1 August 1994
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 62 (2), 343-346
- https://doi.org/10.1016/s0015-0282(16)56889-7
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Improved pregnancy outcome with gonadotropin releasing hormone agonist (GnRH-a) stimulation is due to the improvement in oocyte quantity rather than qualityJournal of Assisted Reproduction and Genetics, 1992
- Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and monkeysFertility and Sterility, 1991
- Ovarian hyporesponsiveness in combined gonadotropin-releasing hormone agonist and menotropin therapy is associated with low serum follicle-stimulating hormone levelsFertility and Sterility, 1991
- Predictive value of hormonal profiles before stimulation for in vitro fertilizationFertility and Sterility, 1989
- Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrievalFertility and Sterility, 1989
- Value of suppression with a gonadotropin-releasing hormone agonist prior to gonadotropin stimulation for in vitro fertilizationFertility and Sterility, 1989
- An alternate approach to controlled ovarian hyperstimulation in “poor responders”: pretreatment with a gonadotropin-releasing hormone analogFertility and Sterility, 1988
- Outcome of in vitro fertilization in women with low response to ovarian stimulationFertility and Sterility, 1987
- Specific binding of luteinizing hormone releasing hormone to human luteal tissueBiochemical and Biophysical Research Communications, 1983